SELLAS Life Sciences (SLS) Preferred Shares Issued (2018)
SELLAS Life Sciences (SLS) reported Preferred Shares Issued of $4.3 million for Q2 2018, down 18.94% on a QoQ basis from $5.3 million in Q1 2018.
SELLAS Life Sciences (SLS) has 1 years of Preferred Shares Issued data on file, last reported at $4.3 million in Q2 2018.
- Quarterly Preferred Shares Issued changed N/A year-over-year to $4.3 million in Q2 2018, while the trailing twelve-month figure through Mar 2019 was $4.3 million (down 18.94% YoY) and the FY2018 annual result came in at $9.6 million, changed N/A from the prior year.
- Preferred Shares Issued declined to $4.3 million in Q2 2018 per SLS's latest filing, from $5.3 million in the prior quarter.
- Across five years, Preferred Shares Issued topped out at $5.3 million in Q1 2018 and bottomed at $4.3 million in Q2 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 4.32 Mn |
| Jun 30, 2018 | 4.32 Mn |
| Mar 31, 2018 | 5.33 Mn |
| Mar 31, 2018 | 5.33 Mn |